The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …

Targeted therapy with epidermal growth factor receptor (EGFR)‑tyrosine kinase inhibitors
(TKIs) is a standard modality of the 1st‑line treatments for patients with advanced EGFR …

Epidermal growth factor receptor (EGFR), the receptor for members of the epidermal growth
factor family, regulates cell proliferation and signal transduction; moreover, EGFR is related …

Osimertinib is an irreversible EGFR-tyrosine kinase inhibitor initially approved for treatment
of EGFR-positive patients exhibiting a T790 M resistance mutation in the second line setting …

The discovery that mutations in the EGFR gene are detected in up to 50% of lung
adenocarcinoma patients, along with the development of highly efficacious epidermal …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) have been first-line
therapy in the treatment of non-small cell lung cancer (NSCLC) harboring EGFR sensitive …

Simple Summary Osimertinib, a third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor, is currently indicated as first-line therapy in patients with non-small …

While significant advancements have been made in the available therapies for metastatic
non-small cell lung cancer (NSCLC), acquired resistance remains a major barrier to …

The pyrimidine core-containing compound Osimertinib is the only epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI) from the third generation that has been …